Skip to main content
. 2017 Jan 12;4(1):e000168. doi: 10.1136/bmjresp-2016-000168

Table 3.

LCI and spirometry before and 90 mins after treatment

  HTS before ACT (n=13)
HTS during ACT (n=13)
Baseline Post MD (95% CI) Rx effect p value Baseline Post MD (95% CI) Rx effect p value
Mean (SD) LCI (no. turnovers) 14.1 (3.6) 14.2 (3.6) 0.10 (−0.59 to 0.79) 0.06 0.75 13.8 (3.4) 13.9 (3.6) 0.12 (−0.42 to 0.66) 0.14 0.49
Mean (SD) FRC (L) 2.24 (0.5) 2.18 (0.5) −0.55 (−0.17 to 0.06) 0.22 0.27 2.20 (0.5) 2.09 (0.5) −0.11 (0.20 to 0.03) 0.40 0.04*
Mean (SD) FEV1% predicted 47.2 (18.9) 48.6 (18.3) 1.38 (−0.61 to 3.38) 0.38 0.05 47.2 (18.2) 48.8 (19.4) 1.64 (−1.06 to 4.34) 0.29 0.14
Mean (SD) FEF25–75% predicted 25.2 (27.5) 26.8 (26.9) 1.54 (−1.41 to 4.48) 0.26 0.18 23.9 (25.6) 27.4 (25.4) 3.46 (−2.80 to 9.72) 0.31 0.11

*p<0.05.

ACT, airway clearance treatment; FEF25–75% predicted, forced expiratory flow 25–75; FEV1% predicted, forced expiratory volume in 1 s; FRC, functional residual capacity; HTS, hypertonic saline; LCI, Lung Clearance Index.